{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-005244","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.629183+00:00","generated_at":"2026-05-27T01:43:56.668823+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"INBS preliminary Q2 revenue $0.61M; six-month gross profit up 32.6% to $0.57M, margin 38.5%","bullets":["Unaudited revenue $0.61M for Q2, $1.48M for six months ended Dec 31, 2024.","Gross profit for six months increased 32.6% to $0.57M; gross margin expanded to 38.5% from 27.7%.","Higher-margin cartridge sales driving profitability; 400+ active accounts.","FDA 510(k) submitted for fingerprint drug screening system to enter U.S. market in 2025.","Calendar 2024 revenue grew 23% year-on-year; expects to file 10-Q in week of Feb 10."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-005244","json":"https://secwatch.observer/filing/0001493152-25-005244.json","markdown":"https://secwatch.observer/filing/0001493152-25-005244.md","text":"https://secwatch.observer/filing/0001493152-25-005244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315225005244/0001493152-25-005244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315225005244/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:43:56.668823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}